Loading clinical trials...
Loading clinical trials...
A Multi-centre, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multiple Oral Dose Titration Study in Patients With Parkinson's Disease to Assess the Efficacy of AFQ056 in Reducing L-dopa Induced Dyskinesias, and the Safety and Tolerability of AFQ056 in Combination With L-dopa
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
Age
30 - 85 years
Sex
ALL
Healthy Volunteers
No
Novartis Investigator Site
Dresden, Germany
Novartis Investigator Site
Kassel, Germany
Novartis Investigator Site
Leun, Germany
Novartis Investigator Site
Marburg, Germany
Novartis Investigator Site
Tübingen, Germany
Start Date
October 1, 2007
Primary Completion Date
May 1, 2008
Last Updated
May 14, 2010
31
ACTUAL participants
AFQ056
DRUG
Placebo
DRUG
Lead Sponsor
Novartis
NCT02119611
NCT07310264
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07216976